Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.

@article{Peng2015IdentificationOL,
  title={Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.},
  author={Sheng-bin Peng and Xiaoyi Zhang and Donald C. Paul and Lisa M Kays and Wendy H. Gough and Julie A. Stewart and Mark T. Uhlik and Qi Chen and Yu-hua Hui and Maciej J. Zamek-Gliszczynski and John A. Wijsman and Kelly M. Credille and Liang Yan},
  journal={Molecular cancer therapeutics},
  year={2015},
  volume={14 2},
  pages={480-90}
}
Emerging evidence demonstrates that stromal cell-derived factor 1 (SDF-1) and CXCR4, a chemokine and chemokine receptor pair, play important roles in tumorigenesis. In this report, we describe a small cyclic peptide, LY2510924, which is a potent and selective CXCR4 antagonist currently in phase II clinical studies for cancer. LY2510924 specifically blocked… CONTINUE READING